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1 Equal contribution.Cell movement requires forces generated by non-muscle myosin II (NM II) for coordinated protru-
sion and retraction. The Cdc42/Rac effector MRCK regulates a speciﬁc actomyosin network in the
lamella essential for cell protrusion and migration. Together with the Rho effector ROK required
for cell rear retraction, they cooperatively regulate cell motility and tumour cell invasion. Despite
the increasing importance of ROK inhibitors for both experimental and clinical purposes, there is
a lack of speciﬁc inhibitors for other related kinases such as MRCK. Here, we report the identiﬁcation
of chelerythrine chloride as a speciﬁc MRCK inhibitor. Its ability to block cellular activity of MRCK
resulted in the speciﬁc loss of NM II-associated MLC phosphorylation in the lamella, and the conse-
quential suppression of cell migration.
Structured summary of protein interactions:
DMPK phosphorylates MYPT by protein kinase assay (View interaction)
PAK alpha phosphorylates MLC by protein kinase assay (View interaction)
MRCK alpha phosphorylates MLC by protein kinase assay (View interaction)
CRIK phosphorylates MLC by protein kinase assay (View interaction)
MRCK beta phosphorylates MLC by protein kinase assay (View interaction)
ROK alpha phosphorylates MLC by protein kinase assay (View Interaction 1, 2)
MRCK beta phosphorylates MYPT by protein kinase assay (View interaction)
MRCK alpha phosphorylates MYPT by protein kinase assay (View interaction)
ROK alpha phosphorylates MYPT by protein kinase assay (View interaction)
MLCK phosphorylates MLC by protein kinase assay (View interaction)
 2011 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Members of the Rho GTPase family are important regulators of
cytoskeletal organization that underlies diverse cellular processes
ranging from migration, differentiation to cell cycle progression
[1,2]. Cell migration in particular requires polarization for the for-
mation of the front-rear axis and generation of force for cell body
translocation [3]. Non-muscle myosin II (NM II) molecules present
in all non-muscle eukaryotic cells are responsible for most of the
contractile forces required for cell body translocation and tail
retraction in cell migration [4]. These bipolar actin-based motoron behalf of the Federation of Euro
arch Partnership, 61 Biopolis
ional University of Singapore,
. Leung).proteins are comprised of a heavy chain and two light chains,
namely the regulatory (MLC) and essential light chains (ELC). Acti-
vation of the catalytic ATPase domain residing in the N-terminus of
the heavy chain relies on the reversible phosphorylation of the
associated MLC on Ser19 (monophosphorylation), or in some cases
on both Thr18 and Ser19 (diphosphorylation) [4]. Besides the ﬁrst
identiﬁed myosin light chain kinase (MLCK) [5], multiple Rho
GTPase effector kinases including Rho kinase (ROK/ROCK/Rho-
kinase) [6,7], citron kinase (CRIK) [8], myotonic dystrophy kinase-
related Cdc42-binding kinase (MRCK) [9], p21-activated kinase (PAK)
[10] have also been shown to activate NM II by phosphorylating
MLC. A PAK-related Misshapen/NIKs-related kinase (MINK) has
also been shown to regulate cytoskeletal organization and cell
motility [11]. In addition, inhibition of myosin phosphatase by
ROK, MRCK and myotonic dystrophy protein kinase (DMPK),
through phosphorylation of its targeting subunit MYPT, is also
important for myosin activation [6,12,13]. Importantly, collectivepean Biochemical Societies.
I. Tan et al. / FEBS Letters 585 (2011) 1260–1268 1261ﬁndings from the studies of these MLC kinases reveal that rather
than playing redundant roles, their separate regulation of NM II
appears to be spatiotemporally distinct and coordinated. CRIK is
primarily involved in the regulation of contractility at the cleavage
furrow and cell cycle progression [8]. For interphase cells, MLCKFig. 1. Inhibition of MRCKa activity by chelerythrine. (A) Structure of chelerythrine chlor
assayed using GST-MLC as substrate, in the presence of increasing concentrations of chele
(C) A graphical representation of the results in (B). Means and standard errors of data
presence or absence of 5 lM chelerythrine. Values represent means and standard erro
measured at 5 lM or 50 lM ATP, in the presence of increasing concentrations of chelerhas been shown to regulate focal complex formation during
lamellipodial extension crucial for leading edge advancement [14,15].
Whereas ROK activity, known for inducing stress ﬁber and focal
adhesion formation, is required for tail retraction and prevention
of cell rear protrusion [16,17], the Cdc42/Rac effector kinase MRCKide. (B) Kinase activity of recombinant catalytic domains of MRCKa and ROKa were
rythrine. Samples were analyzed on SDS–PAGE and the 32P autoradiograph is shown.
are shown. (D) Time course of MLC phosphorylation by MRCKa and ROKa in the
rs of data from three experiments. (E) Kinase activity of MRCKa and ROKa were
ythrine and Y-27632, respectively. Means and standard errors of data are shown.
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myosin network has recently been shown to be essential for lamel-
lar protrusion in a Cdc42-dependent manner, independent of
MLCK and ROK [18]. The ability of these kinases to promote protru-
sion, traction and retraction in different parts of the cell is likely
the result of their unique localization [19]. It is conceivable that
their precise coordination is important for efﬁcient cell movement.
In view of the complex regulation of actomyosin contractility by
multiple protein kinases, it would be useful to develop speciﬁc
inhibitors for each of the kinases involved, in order to gain further
insight into their distinct roles. The widely used ROK inhibitor Y-
27632 is crucial to our understanding of ROK functions. In addition,Fig. 2. Inhibition proﬁle of chelerythrine on MRCK-related kinases. (A) In vitro
Monophosphorylation on Ser19 (pMLC) and diphosphorylation on Thr18/Ser19 (ppM
MYPT-PIM was detected by anti-pMYPT antibody. (B) Activity of various kinases was assa
and PAKa; MBP for PKCa; MYPT-PIM for DMPK and Histone H1 for MINK), in the presenc
by phosphorimager for determining kinase activity. Means and standard errors of datait has been found to be potentially useful for clinical conditions
involving smooth muscle contraction dysfunction [20,21]. As
Rho-ROK and Cdc42-MRCK signaling have been shown to coopera-
tively regulate the invasion of colorectal carcinoma cells into
three-dimensional matrices [22], and that Cdc42-MRCK is impor-
tant for collective invasion of squamous cell carcinoma cells [23],
it is likely that MRCK may also serve as a potential drug target
for blocking tumor cell invasion or metastasis. Here we describe
the identiﬁcation and characterization of chelerythrine chloride
as a speciﬁc inhibitor of MRCK, and its speciﬁc disruptive effects
on MRCK localization, lamellar actomyosin ﬁlaments and cell
migration.phosphorylation of GST-MLC and GST-PIM by various kinases as indicated.
LC) of MLC were detected using speciﬁc phospho-antibodies. Phosphorylation of
yed using appropriate substrates (MLC as substrates for MRCKa/b ROKa, CRIK, MLCK
e of 2 lM or 10 lM chelerythrine. Incorporation of 32P into substrate was measured
from three experiments are shown.
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2.1. cDNA constructs and puriﬁcation of recombinant proteins
Catalytic domains of MRCKa, MRCKb, CRIK, DMPK and MINK1
were cloned in bacterial expression vector pQE60 and expressedFig. 3. Chelerythrine disrupts localization of endogenous MRCK. (A) HeLa cells on covers
ﬁxed and stained for endogenous MRCKa, MYO18A and F-actin (phalloidin). Scale bar:
45 min), Y-27632 (10 lM for 30 min) or a combination of chelerythrine and Y-27632 fo
nucleus (DAPI, in selected images). Scale bar: 20 lm. (C) The degrees of colocalization be
were determined using Metamorph software. Means and standard errors were derived fro
(B) were stained for endogenous MRCKa, ppMLC and F-actin. (E) HeLa cells treated with
indicated times were stained for endogenous MRCKa and F-actin. Scale bar: 20 lm.as C-terminal hexa-His-tagged fusion proteins. Full-length PAKa,
MLC and the phosphorylation inhibitory motif (PIM) of MYPT were
cloned in bacterial expression vector pGEX4T1 and puriﬁed as N-
terminal-tagged GST-fusion proteins. The catalytic domains of
PKCa and ROKa were cloned in mammalian expression vector
pXJ40 and expressed as N-terminal GST-fusion proteins.lips were treated with either DMSO or chelerythrine (7.5 lM for 45 min). Cells were
20 lm. (B) HeLa cells were treated with either DMSO, chelerythrine (7.5 lM for
r 30 min. Cells were ﬁxed and stained for endogenous MRCKa, pMLC, F-actin and
tween MRCKa and pMLC in HeLa cells treated with DMSO, chelerythrine or Y-27632
mmeasurements of 30–40 cells in each category. (D) HeLa cells treated similarly as
either DMSO or chelerythrine (7.5 lM for 30 min) with or without wash-out for the
Fig. 3 (continued)
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from 800 ml IPTG-induced culture. Brieﬂy, bacterial cells were
lysed in a buffer solution containing 25 mM Hepes (pH 7.3),
1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, the protease
inhibitor PMSF and 0.25 mg/ml lysozyme, followed by sonication.
The buffer for puriﬁcation of His-tagged proteins contained
25 mM Imidazole. Post-centrifuged lysates were incubated with
corresponding afﬁnity beads (Ni-NTA agarose or Glutathione-coatedsepharose beads) for 3 h at 4 C. After an extensive wash with
the same lysis buffer, proteins were eluted with the appropriate
elution buffer containing 250 mM Imidazole for His-fusion proteins
or 10 mM Glutathione for GST-fusion proteins. Each of the kinase
domains cloned in the mammalian pXJ40 vector was expressed
in 10 dishes (10 cm diameter) of COS7 cells for 24 h and puriﬁed
essentially as the above-mentioned steps for GST-fusion proteins
(in a 5 times smaller scale).
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Chelerythrine chloride and Y-27632 were obtained from Calbio-
chem. Anti-MRCKamonoclonal antibody (clone 2A3) was obtained
as described [16]. Both anti-pMLC (pSer19) and anti-ppMLC
(ppThr18/Ser19) antibodies were obtained from Cell Signaling
Technology. Anti-pMYPT and anti-GST antibodies were obtained
from Santa Cruz Biotech. and Sigma-Aldrich, respectively.
For immunoblot analysis, 10-30 ng of phosphorylated protein
samples were resolved by SDS–PAGE and transferred onto PVDF
membrane for probing with speciﬁc antibodies as indicated.
2.3. Kinase activity measurements
Kinase assays were carried out at 30 C using appropriate sub-
strates in a buffer containing 10 lM ATP (unless otherwise indi-
cated), 0.2 ll [c-32P]ATP (3000 Ci/mmol; Perkin Elmer), 25 mM
HEPES (pH 7.3), 25 mM KCl, 5 mM b-glycerolphosphate, 2.5 mM
NaF, 5 mM MgCl2, and 0.025% Triton X-100. Radioactive ATP was
excluded from reactions intended for immunoblot analysis. For
the experiment in Fig. 2B, reaction time was 20 min for all kinasesFig. 4. Chelerythrine affects polarized distribution of MRCK, MLC phosphorylation and
stained for F-actin, endogenous MRCKa, and pMLC (top) or ppMLC (bottom). White lines
wound edges treated with 6 lM chelerythrine for 30 min were stained similarly as (A). W
Line scan proﬁles of co-stained MRCKa/bMLC or MRCKa/ppMLC derived from cells treate
6 lM of chelerythrine for 15 min, followed by wounding and subjected to live-cell imagi
bar: 50 lm. (E) Average velocity of migrating cells treated with either DMSO or chelerythr
U2OS cells were exposed to chelerythrine at various concentrations for 12 h. Cell lysateexcept for MRCKa-CAT at 10 min. MLC was used as substrate for
MRCKa/b, ROKa, CRIK, MLCK and PAKa, myelin basic protein
(MBP) was used as PKCa substrate, while GST-MYPT-PIM and His-
tone H1 were for DMPK and MINK1 respectively.
In the initial MRCKa inhibitor screening, a panel of 159 known
chemical compounds (Sigma-Aldrich) at 10 lM each was screened
using Kinase-Glo system (Promega). Reactions in duplicates were
performed in a multi-well plate with 5 lM ATP, 120 ng His-tagged
MRCKa-CAT and 3.5 lg GST-PIM as substrates in a ﬁnal volume of
20 ll. Luminescent signals reﬂecting MRCKa-CAT kinase activity
were measured using Tecan Saﬁre2 microplate reader.
2.4. Cell culture, immunoﬂuorescence and image processing
HeLa and COS7 cells were cultured as described [18]. U2OS cells
were maintained in Dulbecco’s modiﬁed Eagle’s medium with 10%
fetal bovine serum (FBS). For immunoﬂuorescence studies, cells on
cover slips were ﬁxed in 4% paraformaldehyde for 20 min. For
immunostaining of endogenous proteins, the incubation with pri-
mary antibody was carried out for 16 h at 4 C. Alexa 488- and
Alexa 546-conjugated secondary antibodies against mouse andcell motility. (A) U2OS cells at wound edges treated with DMSO for 30 min were
correspond to regions for line scan analysis in (C). Scale bar: 20 lm. (B) U2OS cells at
hite lines correspond to regions for line scan analysis in (C). Scale bar: 20 lm. (C)
d with DMSO or chelerythrine. (D) U2OS cells were pretreated with either DMSO or
ng to follow their migration. Images taken from time 0 h and 10 h are shown. Scale
ine. Values represent means and standard errors of data from three experiments. (F)
s prepared were probed with anti-cleaved caspase-3 antibody.
Fig. 4 (continued)
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Cy3-conjugated anti-mouse and anti-rabbit secondary antibodies
were obtained from Jackson ImmunoResearch Laboratory. Alexa
647-conjugated phalloidin were obtained from Molecular Probes.
All images were captured using a Coolsnap HQ (Roper Scientiﬁc)
adapted to a Zeiss Axioplan wide-ﬁeld ﬂuorescent microscope. Im-
age processing, line scan and colocalization analyses were carried
out using Metamorph software.
2.5. Wound healing assay
U2OS cells at about 90% conﬂuence were starved overnight in
Dulbecco’s modiﬁed Eagle’s medium containing 1% FBS. The result-ing conﬂuent cells were scratched with a pipette tip and replaced
in 10% FBS-containing medium to induce cell migration in the
presence of either DMSO or 6 lM Chelerythrine chloride. The
migration events were followed for 10 to12 h by live recording.
The average migration speed was derived from measurements of
distance traveled using ImagePro software.
3. Results and discussion
3.1. Identiﬁcation of chelerythrine as a potential MRCK inhibitor
In a search for chemical compounds that inhibit MRCK catalytic
activity, chelerythrine chloride was identiﬁed from an in vitro
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inhibitors. As shown in Fig. 1, chelerythrine effectively inhibited
the catalytic domain of MRCKa from phosphorylating MLC on
Ser19 in a concentration-dependent manner (IC50 1.77 lM). A sim-
ilar inhibitory proﬁle was also observed for a closely related com-
pound sanguinarine (IC50 1.25 lM), but no obvious inhibition was
detectable with other related compounds that have fused ABC ring
structures [24] (data not shown). The inhibition was speciﬁc as no
signiﬁcant inhibition was observed for the closely related ROKa ki-
nase (80% homology) under similar conditions (Fig. 1B, C and D).
Unlike ROK inhibition by its inhibitor Y-27632 which became inef-
fective in the presence of high ATP concentration, chelerythrine
inhibition on MRCK was not affected by higher ATP concentration
(Fig. 1E), indicating that it does not act through ATP competition.
3.2. Chelerythrine chloride selectively inhibits MRCK
We next examined the speciﬁcity of chelerythrine more vigor-
ously against a panel of kinases, some of which have been shown
to regulate NM II activity besides ROKa. They include kinases that
share signiﬁcant sequence homology to MRCK such as CRIK and
DMPK, as well as those from different kinase subfamilies like
MLCK, protein kinase C alpha (PKCa), p21-activated kinase alpha
(PAKa) and its related MINK. We ﬁrst determined the substrate
speciﬁcity of each of these kinases in phosphorylating MLC and
the MYPT-PIM using speciﬁc phospho-antibodies (Fig. 2A). We de-
tected Ser19 of MLC as the common phosphorylation site for the
catalytic domains of MRCKa/b, ROKa, MLCK and PAKa, but only
ROKa and CRIK are able to phosphorylate both Thr18 and Ser19
residues causing diphosphorylation. These in vitro data correlate
well with the cellular functions of ROKa and CRIK as the main reg-
ulators of highly contractile processes, such as the actomyosin con-
traction required for cell rear detachment during migration [25]
and the contractile ring formation in cytokinesis crucial for daugh-
ter cells separation [8], as diphosphorylation of MLC has been
shown to further increase myosin’s actin-activated ATPase activity
leading to a higher contractility and ﬁlament assembly [19,26,27].
In contrast, the monophosphorylation of MLC by MLCK, PAK and
MRCK supports their roles in cell edge advancement and lamellar
protrusion [10,14,18]. Likewise, the PIM of MYPT was effectively
phosphorylated by MRCKa/b, ROKa and DMPK (Fig. 2A) [6,12,13].
These ﬁndings suggest that these kinases have the potential to
cooperatively regulate myosin phosphatase activity and to main-
tain the MLC phosphorylation state. The inability of DMPK to phos-
phorylate MLC further suggests that its regulation on myosin
activity may be solely dependent on the inactivation of myosin
phosphatase. Both MINK and PKCa were found incapable of phos-
phorylating any of the three sites on MLC and MYPT probed.
As shown in Fig. 2B, the kinase inhibition proﬁle reveals that be-
sides CRIK and MINK that were partially inhibited by 10 lM chel-
erythrine (50% and 40% inhibition respectively), no signiﬁcant
inhibition was detected for all other kinases examined. In line with
previous reports, the lack of inhibition on PKCa observed conﬁrms
that chelerythrine does not effectively inhibit PKCa activity
[28,29]. Together with a separate proﬁling study (involving 102
individual protein kinases) on chelerythrine speciﬁcity that also
showed no signiﬁcant inhibition of kinases known to directly phos-
phorylate cytoskeletal components (P. Cohen, personal communi-
cation), our ﬁndings indicate that chelerythrine has a high
selectivity towards MRCK.
3.3. Chelerythrine treatment perturbs endogenous MRCK localization
in HeLa cells
We previously showed that MRCK interacts with LRAP35a and
MYO18A, forming a functional complex that colocalizes with andregulates speciﬁc actomyosin networks in the lamella and cell
centre area beneath the nucleus [16]. Therefore, we tested if its
localization and the cytoskeletal networks it regulates are sensitive
to chelerythrine treatment. As shown in Fig. 3A, HeLa cells treated
with 7.5 lM of chelerythrine for 45 min showed signiﬁcantly per-
turbed MRCK and MYO18A localizations. Speciﬁc losses of actomy-
osin networks were also observed in the lamella and subnuclear
region, as revealed by F-actin and monophosphorylated MLC stain-
ing (Fig. 3B and C). Importantly, RhoA/ROK-regulated stress ﬁbers
that contain diphosphorylated MLC were largely unaffected
(Fig. 3D). By contrast, treatment of ROK inhibitor Y-27632 mainly
resulted in the losses of stress ﬁbers and diphosphorylated MLC,
with little effect on MRCK-regulated actomyosin network (Fig. 3B
and D). These observations correlate well with the in vitro ﬁndings
on the mono- and diphosphorylaton of MLC by MRCK and ROK, as
well as the speciﬁcity of chelerythrine and Y-27632 (Fig. 2A and B).
Expectedly, co-treatment of chelerythrine and Y-27632 led to
marked losses of both populations of phosphorylated MLC, result-
ing in an almost complete abolishment of the intracellular actomy-
osin ﬁlaments (Fig. 3B and D). These results strongly suggest that
ROK and MRCK are the two major regulators of cellular actomyosin
structures. The inhibitory effects of chelerythrine therefore mirror
the reported effects of MRCK siRNAs [18], providing further sup-
port that it can inhibit MRCK function in vivo with high speciﬁcity.
Furthermore, chelerythrine inhibition of MRCK is reversible as
shown by the rapid reappearance of speciﬁc MRCK localization
after its removal (Fig. 3E).
3.4. Chelerythrine treatment affects migration of U2OS cells
To further demonstrate the speciﬁcity of MRCK inhibition by
chelerythrine in cell migration, a wound-healing assay on U2OS
cells was performed. Endogenous MRCK in the lamella of migrating
U2OS cells colocalizes signiﬁcantly with monophosphorylated MLC
(Fig. 4A and C) [18]. Together with the underlying F-actin, they
form a speciﬁc network arranged perpendicular to the direction
of wound edge advancement. This is slightly different from its
non-polarized localization in HeLa cells that exhibit multiple
lamellae around most of their periphery [18]. In contrast, the diph-
osphorylated MLC ﬁlaments showed little overlap with MRCK, they
are more enriched in an inner region immediately behind the la-
mella (Fig. 4A and C). Remarkably, chelerythrine treatment almost
completely disrupted the accumulation of MRCK in the lamella,
with a marked drop in the level of monophosphorylated MLC in
the same area (Fig. 4B and C). The level of diphosphorylated MLC
was either not affected or increased moderately upon cheleryth-
rine treatment (Fig. 4B and C). Furthermore, wound edge cells trea-
ted with 6 lM chelerythrine migrated signiﬁcantly slower, with an
average speed of about half of the control cells (Fig. 4D and E). The
lack of detectable cleaved caspase-3 in cells exposed to cheleryth-
rine at up to 10 lM rules out the possible inﬂuence of cell death on
the migration defect (Fig. 4F). Taken together, our results show that
chelerythrine treatment speciﬁcally affected MRCK-mediated MLC
monophosphorylation in the lamella, leading to defective cell
motility. This lends further support to the importance of MRCK
in lamellar actomyosin function.
Here we have found chelerythrine to speciﬁcally perturb lamel-
lar and subnuclear actomyosin ﬁlaments by selectively inhibiting
MRCK. This is different from ROK inhibition by Y-27632 which
mainly affects stress ﬁbers. Although chelerythrine was initially re-
ported as a selective PKC inhibitor [30], two later studies showed
that this is not the case [28,29]. Our work further demonstrates
that it selectively inhibits MRCK over other related kinases. While
chelerythrine has also been shown to be an apoptosis-inducing
agent through its ability to block BclXL-Bak interaction [31], this
effect is only obvious upon a prolonged exposure of more than
1268 I. Tan et al. / FEBS Letters 585 (2011) 1260–126816 h, or to high concentrations. The application of chelerythrine
under our experimental conditions was deemed unlikely to induce
signiﬁcant cell death (Fig. 4). Our initial work on chelerythrine ana-
logs shows that structurally related compounds with fused ABC
rings of chelerythrine are ineffective in inhibiting MRCK while
retaining the ability to induce apoptosis (data not shown), suggest-
ing that the active structural component that directly inhibits
MRCK may lie in the BCD rings portion. Thus, it should be possible
to generate speciﬁc MRCK inhibitors with eliminated cellular
toxicity. With the recent recognition of MRCK as the important
counterpart of ROK in actomyosin regulation [18,22], and the
involvement of these kinases in tumor metastasis [22,23], the iden-
tiﬁcation of chelerythrine as a chemical inhibitor of MRCK should
complement the use of ROK inhibitor Y-27632 in understanding
their distinct but coordinated roles in cellular functions.
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